Amniotic fluid embolism

Disease Description (Causes and Symptoms)

• Definition and pathophysiology: Myeloproliferative neoplasms (MPNs) are a group of disorders characterized by clonal proliferation (originating from a single cell) of hematopoietic cells in the bone marrow, resulting in an excess of one or more of the red blood cells, white blood cells, or platelets. Abnormal proliferation in the bone marrow and the resulting changes in blood components lead to increased blood viscosity, risk of thrombosis, bone marrow fibrosis, and enlargement of peripheral organs (e.g., the spleen).
• Main causes (genetic background): Somatic mutations in JAK2, CALR, and MPL are common (e.g., JAK2 V617F), and some forms are associated with the BCR‑ABL1 fusion gene (chronic myeloid leukemia).
• Main symptoms: The condition may be asymptomatic and discovered incidentally through blood tests. Fatigue and anemia (especially in myelofibrosis), splenomegaly (abdominal fullness and early satiety), thrombosis (such as stroke, myocardial infarction, and venous thrombosis), bleeding (bruising and nosebleeds), facial flushing (polycythemia vera), pruritus (especially after contact with hot water), and peripheral ischemia and pain may occur.

Treatment Methods

• Treatment goals: Prevention of thrombosis, relief of symptoms, control of blood cell counts, and management of the risk of disease progression (myelofibrosis and transformation to acute leukemia).
• Basic treatment principles (summary by disease):
  • Polycythemia vera (PV): The goal is to reduce the risk of thrombosis caused by excess red blood cells. Maintain the hematocrit at less than 45% in men and less than 42% in women through regular phlebotomy (reduction of blood volume). Use low-dose aspirin (generally 75–100 mg/day) to prevent thrombosis. In high-risk patients (age ≥60 years or a history of thrombosis), consider cytoreductive therapy (hydroxyurea is the first choice; interferon may be considered in pregnancy or younger patients). If the patient is refractory or has adverse effects with hydroxyurea, ruxolitinib and other medications may be used (depending on the indication).
  • Essential thrombocythemia (ET): Observation may be appropriate for low-risk patients (age <60 years and no history of thrombosis). If the risk of thrombosis is high or symptoms are present, consider low-dose aspirin (based on individual risk assessment) and cytoreductive therapy (hydroxyurea, anagrelide, or interferon).
  • Primary myelofibrosis (PMF): Provide symptomatic treatment according to symptoms and complications (transfusions for anemia, erythropoietin/hematopoietic stimulants, steroids, etc.). If severe symptoms, reduced hematopoietic function, or splenomegaly is present, use a JAK inhibitor (e.g., ruxolitinib) to reduce symptoms and spleen size. In young patients who meet transplant criteria, allogeneic hematopoietic stem cell transplantation is the only potential cure.
  • Chronic myeloid leukemia (CML): When BCR‑ABL1 is positive, oral tyrosine kinase inhibitors (TKIs; e.g., imatinib, dasatinib, nilotinib, etc.) are the standard first-line treatment.
• Monitoring and lifestyle management: Regular blood tests (CBC), liver and kidney function tests, and, when necessary, bone marrow examinations and molecular genetic tests. Maintain adequate fluid intake, do not smoke, and exercise caution with medications that may increase the risk of thrombosis, such as vitamin K antagonists and hormone medications (especially oral contraceptives). Preconception consultation with a hematologic malignancy specialist is essential.
• Adverse effects and precautions: Management of bone marrow suppression and infection risk from anticancer drugs (such as hydroxyurea), specific adverse effects of TKIs (including skin, liver, and cardiovascular effects), and the risks of bleeding and thrombosis is necessary.

Checklist Before an Outpatient Visit (Including Items to Bring and Sample Questions)

• Items to bring:
  • List of current medications and supplements (including doses and dosing times)
  • Recent blood test results (including CBC) and previous test results (a time series if possible)
  • Past medical history (especially history of thrombosis or bleeding, cardiovascular disease, and liver or kidney disease), and history of surgery or transfusion
  • Family history (blood disorders and thrombosis-related diseases)
  • Symptom records: bleeding or thrombotic symptoms, fatigue, night sweats, abdominal fullness (related to splenomegaly), and itching (especially after bathing)
  • Possibility of pregnancy or pregnancy plans (for women)
• Items to show the doctor during the outpatient visit:
  • Recent CBC results (the trend over the past year if possible) and molecular genetic test results (JAK2/CALR/MPL/BCR‑ABL, etc.)
• Sample questions for tests and preparation (for patients to check themselves):
  • Have I had any symptoms of thrombosis or bleeding within the past 3 months?
  • Do any of my prescription medications or supplements include anticoagulants, hormone medications, or similar drugs?
  • Have there been any recent changes in my weight or symptoms such as heat sensations, night sweats, or itching?

General Sample Questions to Ask the Doctor

• What is the precise basis for the diagnosis of this disease? (Which test results were used to make the diagnosis?)
• What is the target range for my current blood cell counts? How often should I be tested?
• What are the recommended standard treatment options, and what are the advantages and disadvantages (adverse effects) of each?
• What are the common adverse effects and warning signs of this medication (or procedure)? What should I do if a problem occurs?
• I am planning a pregnancy. How should my treatment be adjusted?
• Are there any points I should be careful about regarding lifestyle habits (exercise, diet, smoking, and alcohol consumption)?

Sample Questions Tailored to Each Disease

• For patients with polycythemia vera (PV):
  • What is my current target hematocrit? How often should I undergo phlebotomy (blood donation)?
• For patients with essential thrombocythemia (ET):
  • Based on the assessment of my thrombotic risk, why do you recommend aspirin or cytoreductive therapy (such as hydroxyurea)? How are the criteria for starting treatment (platelet count, age, and medical history) applied?
• For patients with primary myelofibrosis (PMF):
  • What are the indications for hematopoietic stem cell transplantation (allogeneic transplantation), and what are the expected benefits and risks? Do I need an assessment of transplant eligibility?
• For patients with chronic myeloid leukemia (CML):
  • What molecular response (e.g., MMR) is targeted in quantitative BCR‑ABL testing, and when is it expected to be achieved? Under what conditions can discontinuation of medication (treatment discontinuation) be considered?

(Preparing these questions in order of priority according to the clinical situation can make outpatient consultations more efficient.)